WFM
SRPT icon

Wilmington Funds Management’s Sarepta Therapeutics SRPT Stock Holding History

Wilmington Funds Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9,315
Closed -$224K – 816
2014
Q1 		$224K Buy
+9,315
New +$237K 0.02% 634

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Wilmington Funds Management's SRPT Position: Q2 2014 in Review

Wilmington Funds Management sold out of Sarepta Therapeutics (SRPT) in Q2 2014, closing a stake of 9,315 shares — an estimated $224K sold.

Wilmington Funds Management first reported a position in SRPT in Q1 2014 and held it in 1 quarter. The position peaked at $224K in Q1 2014. 128 funds tracked by Wall St. Rank hold SRPT as of Q2 2014.

  • Wilmington Funds Management reported no remaining Sarepta Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Wilmington Funds Management sold 9,315 Sarepta Therapeutics shares in Q2 2014, an estimated $224K.
  • Wilmington Funds Management first reported a position in Sarepta Therapeutics in Q1 2014 and held it in 1 quarter.
  • Wilmington Funds Management's Sarepta Therapeutics position peaked at $224K in Q1 2014.
  • 128 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.